 | Up a level |
Horn, Leora, Rizvi, Naiyer, Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalman, Gerard, Wolf, Juergen, Paik, Paul, Zhu, Jin, Xu, Dong, Neely, Jaclyn, Qi, Zenhao, Harbison, Christopher T., Lynch, Mark and Ramalingam, Suresh S. (2015). LONGER-TERM FOLLOW-UP OF A PHASE 2 STUDY (CHECKMATE 063) OF NIVOLUMAB IN PATIENTS WITH ADVANCED REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC). Asia-Pac. J. Clin. Oncol., 11. S. 124 - 125. HOBOKEN: WILEY-BLACKWELL. ISSN 1743-7563
Horn, Leora, Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Paik, Paul, Li, Ang, Xu, Dong, Neely, Jaclyn, Qi, Zhenhao, Harbison, Christopher, Lynch, Mark and Ramalingam, Suresh S. (2015). Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. J. Thorac. Oncol., 10 (9). S. S175 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380